Presentations & Abstracts
| Cohen C, Molina J-M, Cahn P, Clotet B, Fourie J, Grinsztejn B, Hao W, Johnson M, Saag M, Supparatpinyo K, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. |
|
| Cohen C, Shamblaw D, Ruane P, Elion R, DeJesus E, Liu H, Zhong L, Warren D, Kearney B, Chuck S. Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil rumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Presented at: Seventeenth Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. |
|
| Palleja S, Cohen C, Gathe J, Thompson M, DeJesus E, Brinson C, Elion R, Galindez J, Martin E, Sapirstein J. Safety and efficacy of TBR 652, a CCR5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-naïve patients. Presented at: Seventeenth Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. |
|
| Sheble-Hall S. Community based HIV/AIDS clinical research: implications for the research nurse in a changing business model. Presented at: Twenty-second Annual Conference of the Association of Nurses in AIDS Care; November 18-22, 2009; Jacksonville, FL. |
|
| Green J. A novel and focused approach to Community Advisory Board (CAB) development and maintenance builds community members’ capacity to educate consumers about HIV clinical research, resources, and health maintenance. Presented at: Twenty-second Annual Conference of the Association of Nurses in AIDS Care; November 18-22, 2009; Jacksonville, FL. |
|
| Cohen C, Liporace R, DeJesus E, Khanlou H, Vanig T, Schraeger H, Habel A, Colsen A, Jensen J, Garb J. Use of twice daily darunavir as a substitution for dual boosted PIs in virologically suppressed patients: primary endpoint results of a pilot randomized clinical trial. Presented at: Twelfth European AIDS Conference; November 11-14, 2009; Cologne, Germany. |
|
| Skiest D, Cohen C, Barker D, Gottlieb M, Mounzer K, Bellman P, Dejesus E, Khanlou H, Rashbaum B, Hsiao CB, Ruane P, Abriola K, Bellos N, Ward D, Lalezari J, Santiago F, Garb J, Habel A. Raltegravir without a protease inhibitor is highly efficacious in heavily pre-treated individuals. Presented at: Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa. |
|
| Cohen C, Colson A, Pierone G, Dejesus E, Kinder F, Elion R, Skiest D, Habel A, Jensen J, Garb J, Schrager H, Back D. The FOTO study: The 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients. Presented at: Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa. |
|
| Cohen C, Colson A, Pierone G. The FOTO study: Twenty-Four week results support the safety of a two day break on efavirenz-based antiretroviral therapy. Presented at: Ninth International Congress on Drug Therapy in HIV Infection; November 8-13, 2008; Glasgow, UK. |
|
| Jackson-Pope L, Hussey S, Marston J, Colson A, Cohen CJ. Shifting gears in site management: transforming a clinical trial site into an organization which coordinates multi-site investigator-initiated studies on novel treatment strategies for HIV. Presented at: The Society of Clinical Research Associates, Inc; September 25-28, 2008; Vancouver, BC, Canada. |
Not Available online |
| D Skiest, Krambrink A, Su Z, Robertson K, Havlir D, Margolis D, and the ACTG 5170 team. Patients reported symptoms improve following prolonged treatment interruption: ACTG 5170 quality of life results. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 22-25, 2007; Sydney, Australia. |
|
| Colson AE, Cohen CJ, Stevens R, et al. The impact of changing tenofovir and lamivudine to co-formulated tenofovir and emtricitabine (Truvada) in adults with virologic suppression. Presented at: The 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK. |
|
| Colson AE, Cohen C, McLaughlin K, Habel A, Hellinger JA. The StARS study of once daily Atazanavir, low-dose Ritonavir, and Saquinavir: Impact of changing LPVr to ATVr in combination with SQV. Presented at: The 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September, 2006; San Francisco, California. |
|
| Horne R, Cooper V,Tsoukas C, Katlama C, Cohen C, et al. Injectable therapy in HIV: The role of physician and patient attitudes. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. |
|
| Cohen C, Barbato L, Shapira A, et al. Exploratory analysis of a double-blind randomized trial of dronabinol for nausea in HIV/AIDS patients receiving highly active antiretroviral therapy (HAART). Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. |
|
| Cohen C, Steinhart C, Ward D, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resisitance on the virologic response in study TMC125-C223. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. |
|
| Molina JM, Cohen C, Katlama C, et al. TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. |
|
| Grossman H, Cohen C, Nadler J, et al. Prediction of clinical benefits of TMC125 from treatment effects on CD4 counts and HIV RNA. Presented at: The XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. |
|
| Cohen C, Steinhart CR, Ward DJ, Ruane PJ, Peeters M, Woodfall B. 48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance: Study TMC125-C223. Presented at: Program and Abstracts of the 12th Annual Conference of the British HIV Association; March 29-April 1, 2006; Brighton, United Kingdom. |
Poster
(Registration Required) |
| Skiest D, Havlir D, Coombs R, et al. Predictors of HIV disease progression in patients who stop ART with CD4 cell counts greater than 350 cells per mm3. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. |
|
| DeJesus E, Berger D, Markowitz M, Cohen CJ, et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. |
|
| Berger DS, Bellos N, Farthing C, Stryker R, Colson AE, et al. TMC114/r in 3 class-experienced patients: 24-week primary safety analysis of the power 2 study (C202). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. |
|
| Cohen C, Elion R, DeJesus E, et al, for the COL40263 study team. Week 48 analysis of once-daily (QD) trizivir (TZV) and tenofovir (TDF) in antiretroviral naive subjects (COL40263). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. |
|
| Elion R, Ha B, DeJesus E, Cohen C, et al. Selection of HIV reverse transcriptase (RT) thymidine analogue mutations (TAMS) rather then K65R is the preferred route of resistance seen in patients with virologic failure (VF) for once-daily (QD) trizivir (TZV) and tenofovir (TDF). Presented at: The 45th ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. |
|
| Home R, Clotet B, Cohen C, et al. Treatment-experienced patient perceptions of self-injectable therapy. Presented at: The 10th European AIDS Conference/EACS; November 17-20, 2005; Dublin, Ireland. |
Not Available online |
| Colson A, Hellinger J, Cohen C, et al. The StARS study: Once daily atazanavir, low-dose ritonavir and saquinavir - 24 week efficacy and safety results. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 21-27, 2005; Rio de Janeiro, Brazil. |
|
| Cohen C, Colson A, Morris A, et al. The FOTO study: 48 week viral suppression can be maintained when antiretrovirals are taken for only five consecutive days each week. Presented at: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 21-27, 2005; Rio de Janeiro, Brazil. |
|
| Powderly W, Cohen CJ, Gallant J, et al. Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks. Presented at: The 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. |
|
| Cohen CJ. Comparing a treatment interruption with or without interleukin-2 in delaying a falling CD4+ cell count. The Body Covers: 12th Conference on Retroviruses and Oopportunistic Infections; February 25, 2005; Boston, MA. |
|
| Cohen CJ. Multi-national trial confirms superiority of 3-drug regimen containing efavirenz for the treatment naïve. The Body Covers: 12th Conference on Retroviruses and Opportunistic Infections; February 20, 2005; Boston, MA. |
|
| DeJesus E, Elion R, Cohen CJ, et al. Week 24 analysis of once-daily (QD) trizivir (TZV) and tenofovir DF (TDF) in antiretroviral naïve subjects (COL40263). Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. |
|
| Cohen CJ, Schneider S, Dretler R, et al. Efficacy and safety of switching HIV-1 infected subjects from a protease inhibitor to an efavirenz-based regimen: VEST-QD Week 24 interim results. Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. |
Not Available Online |
| Lalezari JP, Bellos N, Richmond G,Sathasivam K, Cohen C, et al. Final analysis of T1249-102: T-1249 retains potent short-term antiviral activity in patients who have failed a regimen containing enfuviritide. Presented at: The 44th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2; Washington, DC. |
Not Available Online |
| Ward D, Cohen CJ, Keiser P, et al. Efficacy and safety of efavirenz (EFV), lamivudine (3TC), didanosine-EC (DDI-EC), as a once daily regimen for treatment-naïve HIV patients: 48 week results from the DART I trial. Proceedings of The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. |
|
| Cohen CJ, Morris AB, Colson A, et al. The FOTO study: A pilot study of short-cycle treatment interruption, taking antiretroviral medications for five days on, two days off (FOTO) for those with viral load suppression. Presented at: The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. |
|
| Morris AB, Juethner SN, Hellinger J, Cohen CJ. The metabolic abnormalities and cardiovascular risk factors in HIV-infected hispanics in western MA. Proceedings of The XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. |
|
| Elion R, Cohen CJ, DeJesus E, et al. Resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral naïve subjects. Presented at: The Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. |
|
| DeJesus E, Cohen CJ, Sax P, et al. Improvement in quality of life with once-daily didanosine-ED (DDI-ED), lamivudine (3TC), and efavirenz (EFV): 24 week interim results from the DART I Trial. Presented at: The 41st Annual Meeting of Infectious Disease Society of America; October 10, 2003; San Diego, CA. |
|
| DeJesus E, Cohen CJ, Sax P, et al. Efficacy and safety of didanosine-EC (DDI-EC), lamivudine (3TC), and efavirenz (EFV) as a once-daily regimen for treatment-naïve HIV patients: 24-week interim results from the DART I trial. Presented at: The 41st Annual Meeting of Infectious Disease Society of America; October 10, 2003; San Diego, CA. |
|
| Hellinger J, Cohen CJ, Morris AB, et al. A pilot study of saquinavir-SGC (SQV) and lopinavir/ritonavir (LPV/R) twice daily in protease Iinhibitor (PI)-naïve HIV-positive individuals: Protease inhibitor concentrations and week 24 results. Presented at: The 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. |
|
| Cohen CJ, Clumeck N, Molina JM, et al. Impact of enfuvirtide on health-related quality of life. Proceedings of The 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. |
|
| Hellinger JA, Glesby M, Stein A, Morris AJ, Taial A, Tuscher SA, Greenough T, Becker M,Chua A, Cohen CJ, et al. Evaluation of oral pancrelipase (ultrace MT-20) for the symptomatic control of nelfinavir-associated diarrhea. Presented at: The XIV International AIDS Conference; July 2002; Barcelona, Spain. |
|
| Gordon DM, Foy K, Morris AB, Hellinger JA, de Caprariis PJ, Jackson-Pope L, Cohen CJ, et al. Successful management of gastrointestinal (GI) adverse events (AEs) in a prospective trial of ritonavir boosted saquinavir/lopinavir in heavily PI experienced patients. Presented at: The XIV International AIDS Conference; July 2002; Barcelona, Spain. |
|
| Hellinger J, Cohen CJ, Morris AB, et al. A pilot study of saquinavir-SGC (fortovase,SQV) 1000mg and lopinavir/ritonavir (LPV/R) twice daily in protease inhibitor naïve (PIN) HIV-positive individuals. Proceedings of The XIV International AIDS Conference; July, 2002; Barcelona, Spain. |
|
| Sax PE, Islam R, Losina E, Weinstein M, Cohen CJ, et al. Should resistance testing be done in antiretroviral-naïve patients? A cost-effectiveness analysis. Proceedings of The XIV International AIDS Conference; July, 2002. Barcelona, Spain. |
|
| CHellinger JA, Morris AB, Piscitelli S, Gordon D, Foy K, Jackson-Pope L, Cordeir D, Peeters M, Hoetelmans R, de Caprariis PJ and Cohen CJ. Pilot study of saquinavir-SGC (fortovase, SQV) 1000mg twice daly and lopnavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: Dose escalation and combined normalized inhibitory quotient (cNIQ). Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. |
|
| Cameron DW, Angel JB, Ryan J, Jiang P, Rode R, Farthing C, Cohen CJ, et al. Durability of ritonavir (RTV) plus saquinavir (SQV) dual protease inhibitor therapy in HIV infection: 5-year follow-up. Presented at:The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. |
|
| Ross L, Liao Q, Henry K, Cohen CJ, et al. Choice of co-nucleoside analog in d4T-treated subjects may influence the pattern of thmidine analog mutations (TAMs) and multi-nucleoside resisance mutations (MNRs). Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. |
|
| Cohen CJ, Shen Y, Rode R, et al. Effect of nucleoside (NRTI) intensification on prevalence of morphologic abnormalities (MoAs) at year 5 of ritonaivr (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort. Presented at: The 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. |
|
| Murphy L, Katlama C, Belsey EM, Berzins B, Montaner JSG, Harris M, Pollard R, Hellinger JA, Cohen CJ, et al. Antiretroviral activity, toxicity, and pharmacokinetics in patients treated with efavirenz, didanosine, and stavudine with and without hydroxyurea: 48 week results, the 3rd study. Presented at: The 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 28-31, 2001; Athens, Greece. |
Not available online |
| Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GS, Cohen CJ, et al. Primary HIV invection (PHI): Comparing treatment strategies. Presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Illinois. |
Not available online |
| Hellinger JA, Cohen CJ, Squires K, et al. Antiretroviral activity, toxicity, and pharmacokinetics in patients treated with efavirenz, didanosine, and stavudine with and without hydroxyurea: 48 week results, the 3rd study. Presented at: 1st IAS Conference on HIV Pathogenesis and Treatment; June, 2001; Buenos Aires. |
Not Available Online |
| Cohen CJ, Ryan J, Cameron DW, et al. Effect of nucleoside intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in HIV-infection. Proceedings at The 2nd International Workshop on Lipodystrophy and Adverse Effect; October, 2000; Toronto, Canada. |
|
| Losina E, Weinstein MC, Goldie SJ, Seage GR, Walensky RP, Cohen CJ, et al. Sources of variation in model-based life expectancy: Portraying treatment efficacy in HIV disease. Proceedings of The 22nd Annual Meeting for the Society of Medical Decision Making; September 24-27, 2000; Cincinnati, Ohio. |
|
| Verbiest W, Peeters M, Hertogs K, Schel P, Bloor S, Rinehart A, Graham N, Cohen CJ, et al. Virtual phenotype is concordant with actual phenotype: A retrospective analysis of data from VIRA3001. Proceedings of The 40th ICAAC; September 17-20, 2000; Toronto, Canada. |
Not available online |
| Cohen CJ, Sension M, Macko J, et al. Response to highly active antiretroviral therapy (HAART) following prior treatment with saquinavir soft gel capsules. Proceedings of The 40th ICAAC; September 17-20, 2000; Toronto, Canada. |
Not Available Online |
| Freedberg KA, Losina E, Weinstein MC, Goldie SJ, Paltiel A, Cohen CJ, et al. Strategies for HIV care: Clinical impact and cost-effectiveness. Proceedings of The XIIIth International AIDS Conference; July 9-14, 2000; Durban, South Africa. |
|
| Cohen CJ, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA3001). Proceedings of The 4th International Workshop on HIV Drug Resistance and Treatment Strategies; June 12-16, 2000; Sitges, Spain. |
Not Available Online |
| Goldie SJ, Paltiel Ad, Weinstein MC, Losina E, Seage GR, Cohen CJ, et al. Cost-effectiveness of interventions to improve adherence to highly-active antiretroviral therapy (HAART) in HIV-infected patients. Proceedings of The 23rd Annual Meeting of the Society of Genral Internal Medicine; May 4-6, 2000; Boston, MA. |
Not Available Online |
| Cameron DW, Xu Y, Rode R, Cohen CJ, et al. Three-year follow-up and conditional outcomes survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. |
|
| Lalezari J, Beal J, Ruane P, Cohen CJ, et al. Low-dose subcutaneous (SC) IL-2 in combination with HAART therapy induces significant increases in NK cells and naïve t-cells in patients with <300 CD4+ t-cells/mm3: Results of a randomized controlled trial MA-9801. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. |
|
| Cohen CJ, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001). Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. |
|
|
